RU2493150C2 - 2,4-pyrimidine diamine compounds and use thereof - Google Patents
2,4-pyrimidine diamine compounds and use thereof Download PDFInfo
- Publication number
- RU2493150C2 RU2493150C2 RU2008135563/04A RU2008135563A RU2493150C2 RU 2493150 C2 RU2493150 C2 RU 2493150C2 RU 2008135563/04 A RU2008135563/04 A RU 2008135563/04A RU 2008135563 A RU2008135563 A RU 2008135563A RU 2493150 C2 RU2493150 C2 RU 2493150C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- compound according
- alkyl
- heteroaryl
- membered
- Prior art date
Links
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 16
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 102000009438 IgE Receptors Human genes 0.000 claims abstract 2
- 108010073816 IgE Receptors Proteins 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract 2
- 210000002865 immune cell Anatomy 0.000 claims abstract 2
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 102000005962 receptors Human genes 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 230000036647 reaction Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 *c1c(N*)nc(N*)nc1 Chemical compound *c1c(N*)nc(N*)nc1 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FIELD: chemistry.
SUBSTANCE: invention relates to novel of 2,4-pyrimidine diamine compounds of formula I, which inhibit degranulation of immune cells and can be used in treating cell reactions mediated by FcεRI or FcγRl receptors. In formula (I) each R2 and R4 is independently phenyl substituted with one or more R8 groups or a heteroaryl selected from a group consisting of , where the heteroaryl is optionally substituted with one or more R8 groups and at least one of R2 and R4 is a heteroaryl; R5 is selected from a group consisting of (C1-C6)alkyl, optionally substituted with one or more identical or different R8 groups, -ORd, -SRd, fluorine, (C1-C3)halogenalkyloxy, (C1-C3)perhalogenalkyloxy, -NRcRc, (C1-C3)halogenalkyl, -CN, -NO2, -C(O)Rd, -C(O)ORd, -C(O)NRcRc, -C(NH)NRcRc, -OC(O)Rd, -OC(O)ORd, -OC(O)NRcRc; -OC(NH)NRcRc, - [NHC(O)]nORd, R35 is hydrogen or R8; each Y is independently selected from a group consisting of O, S and NH; each Y1 is independently selected from a group consisting of O, S and NH; each Y2 is independently selected from a group consisting of CH, CH2, S, N, NH and NR37. Other values of radicals are given in the claim.
EFFECT: improved efficiency.
19 cl, 6 tbl.
Description
Claims (19)
каждый R2 и R4 независимо представляют собой фенил, замещенный одним или более R8 группами или гетероарил, выбранный из группы, состоящей из
где гетероарил необязательно замещен одной или более R8 группами и, по меньшей мере, один из R2 и R4 представляет собой гетероарил;
R5 выбран из группы, состоящей из (C1-C6)алкила, необязательно замещенного одной или более одинаковыми или разными R8 группами,
-ORd, -SRd, фтор, (C1-C3)галогеналкилокси, (C1-C3)пергалогеналкилокси,
-NRcRc, (C1-C3)галогеналкила, -CN, -NO2, -C(O)Rd, -C(O)ORd, -C(O)NRcRc, -C(NH)NRcRc, -OC(O)Rd, -OC(O)ORd, -OC(O)NRcRc; -OC(NH)NRcRc, - [NHC(O)]nORd,
R35 представляет собой водород или R8;
R8 представляет собой Re, Rb, Re, замещенные одной или более одинаковыми или разными Ra или Rb, -ORa, замещенный одной или более одинаковыми или разными Ra или
Rb, -(CH2)m-Rb, -(CHRa)m-Rb, -O-(CH2)m-Rb, -S-(CH2)m-Rb, -O-CHRaRb, -O-CRa(Rb)2,
-O-(CHRa)m-Rb, -O-(CH2)m-CH[(CH2)m-Rb]Rb, -S-(CHRa)m-Rb,
-C(O)NH-(CH2)m-Rb, -C(O)NH-(CHRa)m-Rb, -O-(CH2)m-C(O)NH-(CH2)m-Rb,
-S-(CH2)m-C(O)NH-(CH2)m-Rb,-O-(CHRa)m-C(O)NH-(CHRa)m-Rb,
-S-(CHRa)m-C(O)NH-(CHRa)m-Rb, -NH-(CH2)m-Rb, -NH-(CHRa)m-Rb,
-NH[(CH2)m-Rb], -N[(CH2)mRb]2, -NH-C(O)-NH-(CH2)m-Rb,
-NH-C(O)-(CH2)m-CHRbRb и -NH-(CH2)m-C(O)-NH-(CH2)m-Rb;
каждый Ra независимо выбран группы, состоящей из водорода, (C1-C6)алкила, (C3-C8)циклоалкила, (C4-C11)циклоалкилалкила, фенила или нафтила, (C7-C16)арилалкила, 2-6-членного гетероалкила, включающего 1-3 гетероатома, выбранных из O, S или N, 3-8-членного циклогетероалкила, включающего 1-3 гетероатома, выбранных из O, S или N, 4-11-членного циклогетероалкилалкила, включающего 1-3 гетероатома, выбранных из O, S или N, 5-10-членного гетероарила, включающего 1-3 гетероатома, выбранных из O, N или S, и 6-16-членного гетероарилалкила, где гетероарил представляет собой 5-10-членный гетероарил, включающий 1-3 гетероатома, выбранных из O, N или S;
каждый Rb представляет собой группу, независимо выбранную из группы, состоящей из =O, -ORd, (C1-C3)галогеналкилокси, -OCF3, -NRcRc,
галогена, -CF3, -CN, -NC, -C(O)ORd, -C(NOH)Ra, -OC(O)Rd, -OC(O)ORd-,
-[NHC(O)]nRd, -[NRaC(O)]nRd, - [NHC(O)]nORd, - [NRaC(O)]nORd, -[NHC(O)]nNRcRc, -[NRaC(O)]nNRcRc;
каждый Rc является независимо Ra, или, альтернативно, два Rc, взятые вместе с атомом азота, к которому они присоединены, образуют 5-8-членный циклогетероалкил, включающий 1-3 гетероатома, выбранных из O, S или N, или 5-10-членный гетероарил, включающий 1-3 гетероатома, выбранных из O, N или S, которые необязательно могут включать один или более одинаковых или разных дополнительных гетероатомов и которые необязательно могут быть замещены одним или более одинаковыми или разными Ra или Rb группами;
каждый Rd независимо является Ra;
каждый Re необязательно выбирают из группы, состоящей из (C1-C6)алкила, (C3-C8)циклоалкила, (C4-C11)циклоалкилалкила, фенила или нафтила, (C7-C16) арилалкила, 2-6-членного гетероалкила, включающего 1-3 гетероатома, выбранных из O, S или N, 3-8-членного циклогетероалкила, включающего 1-3 гетероатома, выбранных из O, S или N, 4-11-членного циклогетероалкилалкила, включающего 1-3 гетероатома, выбранных из O, S или N, 5-10-членного гетероарила, включающего 1-3 гетероатома, выбранных из O, N или S, и 6-16-членного гетероарилалкила, где гетероарил представляет собой 5-10-членный гетероарил, включающий 1-3 гетероатома, выбранных из O, N или S;
каждый Y независимо выбран из группы, состоящей из O, S и NH;
каждый Y1 независимо выбран из группы, состоящей из O, S и NH;
каждый Y2 независимо выбран из группы, состоящей из CH, CH2, S, N, NH и NR37;
R36 представляет собой водород или (C1-С6)алкил;
R37 представляет собой водород;
причем в определениях арилалкил - арил представляет собой фенил или нафтил; а алкил - (C1-С6)алкил;
каждый m независимо является целым числом от 1 до 3; и каждый n независимо является целым числом от 0 до 3.1. The compound of formula I:
each R 2 and R 4 independently represents phenyl substituted with one or more R 8 groups or heteroaryl selected from the group consisting of
wherein heteroaryl is optionally substituted with one or more R 8 groups and at least one of R 2 and R 4 is heteroaryl;
R 5 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more identical or different R 8 groups,
-OR d , -SR d , fluoro, (C1-C3) haloalkyloxy, (C1-C3) perhaloalkyloxy,
-NR c R c , (C1-C3) haloalkyl, -CN, -NO 2 , -C (O) R d , -C (O) OR d , -C (O) NR c R c , -C (NH ) NR c R c , -OC (O) R d , -OC (O) OR d , -OC (O) NR c R c ; —OC (NH) NR c R c , - [NHC (O)] n OR d ,
R 35 represents hydrogen or R 8 ;
R 8 represents R e , R b , R e substituted by one or more identical or different R a or R b , -OR a substituted by one or more identical or different R a or
R b , - (CH 2 ) m -R b , - (CHR a ) m -R b , -O- (CH 2 ) m -R b , -S- (CH 2 ) m -R b , -O- CHR a R b , -O-CR a (R b ) 2 ,
-O- (CHR a ) m -R b , -O- (CH 2 ) m -CH [(CH 2 ) m -R b ] R b , -S- (CHR a ) m -R b ,
-C (O) NH- (CH 2 ) m -R b , -C (O) NH- (CHR a ) m -R b , -O- (CH 2 ) m -C (O) NH- (CH 2 ) m -R b ,
-S- (CH 2 ) m -C (O) NH- (CH 2 ) m -R b , -O- (CHR a ) m -C (O) NH- (CHR a ) m -R b ,
-S- (CHR a ) m -C (O) NH- (CHR a ) m -R b , -NH- (CH 2 ) m -R b , -NH- (CHR a ) m -R b ,
-NH [(CH 2 ) m -R b ], -N [(CH 2 ) m R b ] 2 , -NH-C (O) -NH- (CH 2 ) m -R b ,
-NH-C (O) - (CH 2 ) m -CHR b R b and -NH- (CH 2 ) m -C (O) -NH- (CH 2 ) m -R b ;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C4-C11) cycloalkylalkyl, phenyl or naphthyl, (C7-C16) arylalkyl, 2-6 membered heteroalkyl, comprising 1-3 heteroatoms selected from O, S or N, a 3-8 membered cycloheteroalkyl, comprising 1-3 heteroatoms selected from O, S or N, a 4-11 membered cycloheteroalkylalkyl comprising 1-3 heteroatoms selected from O, S or N, a 5-10 membered heteroaryl comprising 1-3 heteroatoms selected from O, N or S, and a 6-16 membered heteroarylalkyl, wherein the heteroaryl is a 5-10 membered hetero aryl comprising 1-3 heteroatoms selected from O, N or S;
each R b represents a group independently selected from the group consisting of = O, -OR d , (C1-C3) haloalkyloxy, -OCF 3 , -NR c R c ,
halogen, —CF 3 , —CN, —NC, —C (O) OR d , —C (NOH) R a , —OC (O) R d , —OC (O) OR d -,
- [NHC (O)] n R d , - [NR a C (O)] n R d , - [NHC (O)] n OR d , - [NR a C (O)] n OR d , - [ NHC (O)] n NR c R c , - [NR a C (O)] n NR c R c ;
each R c is independently R a , or, alternatively, two R c , taken together with the nitrogen atom to which they are attached, form a 5-8 membered cycloheteroalkyl comprising 1-3 heteroatoms selected from O, S or N, or 5-10 membered heteroaryl, including 1-3 heteroatoms selected from O, N or S, which optionally may include one or more identical or different additional heteroatoms and which may optionally be substituted with one or more identical or different R a or R b in groups;
each R d is independently R a ;
each R e is optionally selected from the group consisting of (C1-C6) alkyl, (C3-C8) cycloalkyl, (C4-C11) cycloalkylalkyl, phenyl or naphthyl, (C7-C16) arylalkyl, 2-6 membered heteroalkyl, including 1-3 heteroatoms selected from O, S or N, a 3-8 membered cycloheteroalkyl, including 1-3 heteroatoms selected from O, S or N, a 4-11 membered cycloheteroalkylalkyl comprising 1-3 heteroatoms selected from O , S or N, a 5-10 membered heteroaryl comprising 1-3 heteroatoms selected from O, N or S, and a 6-16 membered heteroarylalkyl, wherein the heteroaryl is a 5-10 membered hetero Ryl comprising 1-3 heteroatoms selected from O, N or S;
each Y is independently selected from the group consisting of O, S, and NH;
each Y 1 is independently selected from the group consisting of O, S, and NH;
each Y 2 is independently selected from the group consisting of CH, CH 2 , S, N, NH, and NR 37 ;
R 36 represents hydrogen or (C1-C6) alkyl;
R 37 represents hydrogen;
moreover, in the definitions of arylalkyl - aryl represents phenyl or naphthyl; and alkyl is (C1-C6) alkyl;
each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3.
2. The compound according to claim 1, where heteroaryl is selected from
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35333302P | 2002-02-01 | 2002-02-01 | |
| US35326702P | 2002-02-01 | 2002-02-01 | |
| US60/353,267 | 2002-02-01 | ||
| US60/353,333 | 2002-02-01 | ||
| US39967302P | 2002-07-29 | 2002-07-29 | |
| US60/399,673 | 2002-07-29 | ||
| US43427702P | 2002-12-17 | 2002-12-17 | |
| US60/434,277 | 2002-12-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004126431/04A Division RU2343148C2 (en) | 2002-02-01 | 2003-01-31 | Compounds of 2,4-pyrimidindiamines and their application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008135563A RU2008135563A (en) | 2010-03-10 |
| RU2493150C2 true RU2493150C2 (en) | 2013-09-20 |
Family
ID=35846582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004126431/04A RU2343148C2 (en) | 2002-02-01 | 2003-01-31 | Compounds of 2,4-pyrimidindiamines and their application |
| RU2008135563/04A RU2493150C2 (en) | 2002-02-01 | 2008-09-02 | 2,4-pyrimidine diamine compounds and use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004126431/04A RU2343148C2 (en) | 2002-02-01 | 2003-01-31 | Compounds of 2,4-pyrimidindiamines and their application |
Country Status (1)
| Country | Link |
|---|---|
| RU (2) | RU2343148C2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579892A (en) * | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
| TWI389893B (en) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
| JP6184423B2 (en) | 2012-05-18 | 2017-08-23 | 大日本住友製薬株式会社 | Carboxylic acid compound |
| DK2970205T3 (en) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2 and ALK2 inhibitors and methods for their use |
| WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
| CN112512597A (en) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | Methods for treating diseases associated with aberrant ACVR1 expression and ACVR1 inhibitors useful therefor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03127790A (en) * | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N-(1h-tetrazol-5-yl)-2-anilino-5-pyrimidinecarboxamides and synthetic intermediate therefor |
| EP1054004A1 (en) * | 1997-12-15 | 2000-11-22 | Yamanouchi Pharmaceutical Co. Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| RU2376992C2 (en) * | 2002-07-29 | 2009-12-27 | Райджел Фармасьютикалз, Инк. | Methods of treatment or prevention of autoimmune diseases by means of 2,4-pyrimidindiamin compounds |
-
2003
- 2003-01-31 RU RU2004126431/04A patent/RU2343148C2/en active
-
2008
- 2008-09-02 RU RU2008135563/04A patent/RU2493150C2/en active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03127790A (en) * | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N-(1h-tetrazol-5-yl)-2-anilino-5-pyrimidinecarboxamides and synthetic intermediate therefor |
| EP1054004A1 (en) * | 1997-12-15 | 2000-11-22 | Yamanouchi Pharmaceutical Co. Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| RU2376992C2 (en) * | 2002-07-29 | 2009-12-27 | Райджел Фармасьютикалз, Инк. | Methods of treatment or prevention of autoimmune diseases by means of 2,4-pyrimidindiamin compounds |
Non-Patent Citations (4)
| Title |
|---|
| КАРП В.К. и др. Синтез и противовоспалительные свойства о-карбоксифениламинопиримидины. - Химико-фармацевтический журнал, 1983, 17(11), с.1304-1307. * |
| ПОПОВА Л.М. и др. Реакции 2,4,6-трифторпропилпиримидинов и 4-аминодифторпиримидинов с этиламином. - ЖорХ, 1996, 32(5), с.781-787. * |
| ПОПОВА Л.М. и др. Синтез и свойства 2,4-дизамещенные-6-фторпиримидинов. - ЖорХ, 1996, 32(9), с.1424-1429. * |
| ПОПОВА Л.М. и др. Синтез и свойства 2,4-дизамещенные-6-фторпиримидинов. - ЖорХ, 1996, 32(9), с.1424-1429. ПОПОВА Л.М. и др. Реакции 2,4,6-трифторпропилпиримидинов и 4-аминодифторпиримидинов с этиламином. - ЖорХ, 1996, 32(5), с.781-787. КАРП В.К. и др. Синтез и противовоспалительные свойства о-карбоксифениламинопиримидины. - Химико-фармацевтический журнал, 1983, 17(11), с.1304-1307. ТРЕТЬЯКОВА Г.С. и др. Синтез и стимулирующая активность адамантиламинопроизводных 2,4,6-триамино-5-нитропиримидинов и их аналогов. - Физиологически активные вещества, 1980, 12, с.63-67. ГРИГОРЬЕВА А.С. и др. Аминооксидазная активность церулоплазмина и комплексы меди (II) с производными антраниловой кислоты. - Химико-фармацевтический журнал, 1980, 14(8), с.7-11. ГРИГОРЬЕВА А.С. и др. Изучение реакций церулоплазмина с нестероизными противовоспалительными препаратами - производными антраниловой кислоты. - Химико-фармацевтический журнал, 1979, 13(3), с.5-10. Online! ACS on STN: Chemical Abstracts, v.88: ref. 151 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2343148C2 (en) | 2009-01-10 |
| RU2008135563A (en) | 2010-03-10 |
| RU2004126431A (en) | 2005-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2493150C2 (en) | 2,4-pyrimidine diamine compounds and use thereof | |
| RU2009140324A (en) | PRODUCTION OF SILICON AND GERMANY PHTHALOCIANINES AND RELATED SUBSTANTIES | |
| RU2004124711A (en) | METHOD FOR PRODUCING INDOLINONE DERIVATIVES | |
| EA199700416A1 (en) | BICYCLIC AMINES AND THEIR APPLICATION AS INSECTICIDES | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| RU2004120553A (en) | NICOTINAMIDE DERIVATIVES USEFUL AS P38 INHIBITORS | |
| RU2000120162A (en) | ARYL-AND HETEROARYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES OF UREA, A METHOD FOR TREATING DISEASES MEDIATED BY RAIN KINASE, PHARMACEUTICAL COMPOSITION | |
| JP2004526700A5 (en) | ||
| RU2011129325A (en) | Cyclic carbide imide compound | |
| EP1063228A4 (en) | CYCLOALK DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE | |
| SK23495A3 (en) | Sulphinilating method of heterocyclic compounds and intermediates in this method | |
| EP1826196A3 (en) | Vinyl ether compounds | |
| RU2000125568A (en) | DERIVATIVES OF CYCLOALKENES, THEIR RECEPTION AND APPLICATION | |
| ATE327994T1 (en) | MESO-SUBSTITUTED TRIPYRRANE DERIVATIVES, COMPOSITIONS AND POSSIBLE USES AND METHOD FOR THE PRODUCTION THEREOF | |
| ES8700856A1 (en) | A PROCEDURE FOR THE PREPARATION OF 1, 4-DIHYDROPYRIDINE COMPOUNDS | |
| RU2006121438A (en) | METHOD FOR OBTAINING BISPHOSPHOLAN LIGANDS | |
| RU2301229C2 (en) | Method for preparing derivatives of 2-(6-substituted-1,3-dioxane-4-yl)-acetic acid | |
| RU2011149550A (en) | COMPOUNDS OF O-IMINO-ISOMOUROUS AND THEIR POLYMERIZABLE COMPOSITIONS | |
| WO2009062171A1 (en) | Preparation of saturated imidazolinium salts and related compounds | |
| SE8406302L (en) | NEW AMINOGUANIDE DERIVATIVES AND A PROCEDURE FOR THEIR PREPARATION | |
| RU2004130300A (en) | METHOD FOR SYNTHESIS OF CHIRAL N-ARILPIPERAZINES | |
| Aghahosseini et al. | Heteroaromatic aldehydes with unprecedented catalytic performance in selective radical reactions: synthesis of α‐aminophosphonate scaffolds | |
| RU2001103751A (en) | METHODS FOR PRODUCING 2-AMINO-4-CHLORINE-1,3,5-TRIAZINES | |
| RU99100377A (en) | NEW AROMATIC DERIVATIVES, FILLED WITH RIBOSE, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS A MEDICINE | |
| ATE261441T1 (en) | ANALOGUES OF DISTAMYCIN CINNAMIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTI-TUMOR AGENTS |